Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Antibodies are the most rapidly growing drug class and have a major impact on human health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of the best understood and most tractable cell surface and secreted targets with known roles in human diseases have been extensively exploited for antibody drug development. In this Review, we focus on emerging and novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody–drug conjugates, bispecific antibodies and antibody engineering to facilitate more effective delivery. These strategies could enable the pursuit of difficult to hit, less well-understood or previously undruggable targets — the 'high-hanging fruit'.

[1]  K. Jensen,et al.  In vitro and ex vivo strategies for intracellular delivery , 2016, Nature.

[2]  Qing Chai,et al.  Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. , 2015, Protein engineering, design & selection : PEDS.

[3]  P. Moore,et al.  A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.

[4]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[5]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[6]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[7]  R. Carano,et al.  Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia , 2013, PloS one.

[8]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[9]  S. Shin,et al.  Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration , 2017, Nature Communications.

[10]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[11]  A. Strosberg,et al.  Monoclonal antibodies to purified muscarinic receptor display agonist-like activity. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Cragg,et al.  Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization , 2014, The Journal of Immunology.

[13]  P. Diot,et al.  The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors , 2011, Pharmaceutical Research.

[14]  A. Lukashin,et al.  Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. , 2006, Cancer research.

[15]  A. Tolcher Antibody drug conjugates: lessons from 20 years of clinical experience. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. Abbott,et al.  Failed Alzheimer’s trial does not kill leading theory of disease , 2016, Nature.

[17]  C. Uyttenhove,et al.  PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species. , 2017, International journal of pharmaceutics.

[18]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[19]  Andreas Plückthun,et al.  A quantitative comparison of cytosolic delivery via different protein uptake systems , 2017, Scientific Reports.

[20]  M. Boyle,et al.  Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. , 1997, Blood.

[21]  C. Witmer,et al.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence , 2013, Therapeutic advances in hematology.

[22]  Janice M. Reichert,et al.  Antibodies to watch in 2017 , 2016, mAbs.

[23]  C. Riccardi,et al.  Pharmacological modulation of GITRL/GITR system: therapeutic perspectives , 2012, British journal of pharmacology.

[24]  Rachel M. Devay,et al.  Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9* , 2012, The Journal of Biological Chemistry.

[25]  J. Zapata,et al.  T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes , 2013, The Journal of Immunology.

[26]  A. Coxon,et al.  Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types , 2010, Cancer biology & therapy.

[27]  R. Foà,et al.  Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics , 2013, mAbs.

[28]  P. Burke,et al.  Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index , 2015, Nature Biotechnology.

[29]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[30]  N. Bodyak,et al.  A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy. , 2015, Cancer research.

[31]  A. Baruch,et al.  FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases , 2017, Hormone molecular biology and clinical investigation.

[32]  T. Arora,et al.  Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex , 2012, Science Translational Medicine.

[33]  Jeffrey R. Chabot,et al.  A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. , 2016, Cell metabolism.

[34]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[35]  M. Cragg,et al.  Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.

[36]  M. Satoh,et al.  The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. , 2015, Journal of pharmaceutical sciences.

[37]  Qing-hui Zhou,et al.  Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. , 2010, Molecular pharmaceutics.

[38]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[39]  A. Ford,et al.  Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials , 2013, The American Journal of Gastroenterology.

[40]  Ryan L. Kelly,et al.  Chaperone proteins as single component reagents to assess antibody nonspecificity , 2017, mAbs.

[41]  J. Wolchok,et al.  Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .

[42]  L. Weiner,et al.  Mechanisms of action of therapeutic antibodies for cancer. , 2015, Molecular immunology.

[43]  J. Ravetch,et al.  Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.

[44]  P. Freskgård,et al.  Antibody therapies in CNS diseases , 2017, Neuropharmacology.

[45]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[46]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[47]  A. Yang,et al.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. , 2011, Cancer cell.

[48]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[49]  M. Chiu,et al.  Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody , 2016, mAbs.

[50]  K Dane Wittrup,et al.  Target-independent variable region mediated effects on antibody clearance can be FcRn independent , 2016, mAbs.

[51]  Albert Torri,et al.  Antidrug Antibodies in Patients Treated with Alirocumab. , 2017, The New England journal of medicine.

[52]  Z. Johnson,et al.  Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[54]  P. Ridker,et al.  Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab , 2017, The New England journal of medicine.

[55]  Anirvan Ghosh,et al.  Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.

[56]  D. Chang,et al.  Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies* , 1996, The Journal of Biological Chemistry.

[57]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[58]  Melissa L Geddie,et al.  A novel screening method to assess developability of antibody-like molecules , 2015, mAbs.

[59]  A. Mitra,et al.  How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches , 2017, Expert opinion on drug delivery.

[60]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[61]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[62]  M. P. Griffin,et al.  A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.

[63]  J. Ravetch,et al.  Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo , 2013, Proceedings of the National Academy of Sciences.

[64]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Bylesjo,et al.  Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab , 2015, Journal of Immunotherapy for Cancer.

[66]  Xiaotong Wang,et al.  Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations , 2013, Genome biology and evolution.

[67]  A. D. de Fougerolles,et al.  Nanobodies®† as inhaled biotherapeutics for lung diseases , 2017, Pharmacology & therapeutics.

[68]  A. Holdorf,et al.  AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[69]  H. Kettenberger,et al.  Developability assessment during the selection of novel therapeutic antibodies. , 2015, Journal of pharmaceutical sciences.

[70]  T. Igawa,et al.  Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.

[71]  P. Parren,et al.  Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells , 2017, The Journal of Immunology.

[72]  E. M. Cook,et al.  Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions , 2016, The Journal of Immunology.

[73]  K. Amighi,et al.  Inhaled proteins: challenges and perspectives. , 2013, International journal of pharmaceutics.

[74]  P. Baeuerle,et al.  Targeting T cells to tumor cells using bispecific antibodies. , 2013, Current opinion in chemical biology.

[75]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[76]  W. Pardridge,et al.  CSF, blood-brain barrier, and brain drug delivery , 2016, Expert opinion on drug delivery.

[77]  N. Bartlett,et al.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[78]  Carol F. Kirchhoff,et al.  Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence , 2016, BioDrugs.

[79]  J Feldschuh,et al.  Prediction of the Normal Blood Volume: Relation of Blood Volume to Body Habitus , 1977, Circulation.

[80]  A. West,et al.  Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. , 2013, Cell reports.

[81]  M. Schrappe,et al.  The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients , 2013, Leukemia.

[82]  D. Irvine,et al.  Delivering safer immunotherapies for cancer , 2017, Advanced drug delivery reviews.

[83]  Gary D Bader,et al.  A draft map of the human proteome , 2014, Nature.

[84]  K. Gadkar,et al.  Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics. , 2015, Investigative ophthalmology & visual science.

[85]  J. Wolchok,et al.  Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Y. Vugmeyster,et al.  Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species , 2011, Pharmaceutical Research.

[87]  Carlos Pineda,et al.  Assessing the Immunogenicity of Biopharmaceuticals , 2016, BioDrugs.

[88]  L. Aiello,et al.  RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.

[89]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[90]  U. Nielsen,et al.  Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic , 2015, Molecular Cancer Therapeutics.

[91]  Jean-Christophe Leroux,et al.  Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts. , 2016, Advanced drug delivery reviews.

[92]  Jeffrey S Wagener,et al.  Dornase alfa (Pulmozyme) , 2012, Current opinion in pulmonary medicine.

[93]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[94]  K. Scearce-Levie,et al.  Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.

[95]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[96]  S. Lacy,et al.  The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity , 2008, The Journal of Immunology.

[97]  Z. Sauna,et al.  Immunogenicity assessment during the development of protein therapeutics , 2018, The Journal of pharmacy and pharmacology.

[98]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[99]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[100]  M. Chiu,et al.  Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody* , 2016, The Journal of Biological Chemistry.

[101]  Ulrich Brinkmann,et al.  The making of bispecific antibodies , 2017, mAbs.

[102]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[103]  L. Zitvogel,et al.  Rationale for anti-OX40 cancer immunotherapy. , 2016, European journal of cancer.

[104]  R. Million,et al.  Monoclonal antibody biosimilars , 2015, Nature Reviews Drug Discovery.

[105]  G. Sármay,et al.  Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19 , 2014, mAbs.

[106]  Ying Tang,et al.  The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies , 2015, mAbs.

[107]  D. Neri,et al.  Immunocytokines for cancer treatment: past, present and future. , 2016, Current opinion in immunology.

[108]  W. Pardridge,et al.  Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies , 2016, Expert opinion on biological therapy.

[109]  W. Xu,et al.  Developability studies before initiation of process development , 2013, mAbs.

[110]  Scott R. Presnell,et al.  Engineering of stable bispecific antibodies targeting IL-17A and IL-23. , 2009, Protein engineering, design & selection : PEDS.

[111]  T. Dryja,et al.  Long-acting protein drugs for the treatment of ocular diseases , 2017, Nature Communications.

[112]  F. Malavasi,et al.  Antibody mimicry, receptors and clinical applications. , 2017, Human antibodies.

[113]  Y. Vugmeyster,et al.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.

[114]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[115]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[116]  Matthew J. Brauer,et al.  Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex , 2015, EBioMedicine.

[117]  Mark R Prausnitz,et al.  Ocular delivery of macromolecules. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[118]  R. Chanock,et al.  Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats , 1987, Journal of virology.

[119]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[120]  T. Igawa,et al.  Reduced elimination of IgG antibodies by engineering the variable region. , 2010, Protein engineering, design & selection : PEDS.

[121]  P. Carter,et al.  Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.

[122]  R. Minter,et al.  A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency , 2012, Cell Death and Differentiation.

[123]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[124]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[125]  T. Wilkinson,et al.  Discovery of Functional Antibodies Targeting Ion Channels , 2015, Journal of biomolecular screening.

[126]  E. Remaut,et al.  Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis , 2010, Mucosal Immunology.

[127]  E. Lemarié,et al.  VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations , 2014, mAbs.

[128]  R. Vonderheide,et al.  Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer , 2013, Cancer Immunology Research.

[129]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[130]  Chunning Yang,et al.  Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence , 2017, Scientific Reports.

[131]  C. Yang,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.

[132]  K. Tsumoto,et al.  Structural analysis of Fc/FcγR complexes: a blueprint for antibody design , 2015, Immunological reviews.

[133]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[134]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[135]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[136]  Sandeep Kumar,et al.  Potential aggregation prone regions in biotherapeutics , 2009, mAbs.

[137]  P. Diot,et al.  Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[138]  Herren Wu,et al.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. , 2007, Journal of molecular biology.

[139]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[140]  B. Pentelute,et al.  Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen , 2014, Chembiochem : a European journal of chemical biology.

[141]  M. Rebelatto,et al.  A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. , 2016, Cancer cell.

[142]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[143]  C. Ware,et al.  Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2 , 2005, Clinical Cancer Research.

[144]  R. Majeti,et al.  A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.

[145]  L. Khawli,et al.  Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics* , 2015, The Journal of Biological Chemistry.

[146]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[147]  W. Hiddemann,et al.  Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.

[148]  Diego Ellerman,et al.  Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.

[149]  J. Dye,et al.  A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses , 2016, Science.

[150]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[151]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[152]  H. Lyerly,et al.  CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1 , 2015, Cancer Immunology, Immunotherapy.

[153]  C. J. Hutchings,et al.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors , 2017, Nature Reviews Drug Discovery.

[154]  M. Tabrizi,et al.  Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.

[155]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[156]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[157]  K. Shitara,et al.  Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.

[158]  P. Parren,et al.  Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. , 2006, Cancer research.

[159]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[160]  R. Kelley,et al.  Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates , 2017, mAbs.

[161]  Anuj Chaudhri,et al.  Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. , 2015, Molecular pharmaceutics.

[162]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[163]  Louis P Garrison,et al.  Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[164]  H. Kohrt,et al.  4-1BB agonism: adding the accelerator to cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[165]  Qing-hui Zhou,et al.  Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse , 2010, Drug Metabolism and Disposition.

[166]  A. Ashkenazi,et al.  Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies , 2013, The Journal of experimental medicine.

[167]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[168]  F. Bootz,et al.  Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. , 2016, Drug discovery today.

[169]  H. Miyazaki,et al.  Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor , 2008, Nature Biotechnology.

[170]  Olga Obrezanova,et al.  Aggregation risk prediction for antibodies and its application to biotherapeutic development , 2015, mAbs.

[171]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[172]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[173]  W. Pardridge,et al.  Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.

[174]  P. Humphries,et al.  The blood-retina barrier: tight junctions and barrier modulation. , 2012, Advances in experimental medicine and biology.

[175]  D D Allen,et al.  The blood-brain barrier and brain drug delivery. , 2006, Journal of nanoscience and nanotechnology.

[176]  Matthew R. Levengood,et al.  Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.

[177]  Rony Dahan,et al.  Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. , 2016, Cancer cell.

[178]  A. D. Nielsen,et al.  Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[179]  Jennifer B. Webster,et al.  Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. , 2006, Protein engineering, design & selection : PEDS.

[180]  Yu Cao,et al.  An immunosuppressive antibody-drug conjugate. , 2015, Journal of the American Chemical Society.

[181]  A. Plückthun,et al.  Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[182]  G. V. Vande Woude,et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.

[183]  A. Cheng-Lai,et al.  Inhaled Insulin: A Clinical and Historical Review , 2017, Cardiology in review.

[184]  T. Arvedson,et al.  Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing , 2017 .

[185]  Alexandra Lavoisier,et al.  Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection , 2014, mAbs.

[186]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[187]  J. Zenilman,et al.  Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A , 2014, Antimicrobial Agents and Chemotherapy.

[188]  Eugene A Zhukovsky,et al.  Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. , 2016, Current opinion in immunology.

[189]  A. Datta-Mannan,et al.  Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics , 2015, mAbs.

[190]  L. Schwartz,et al.  Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. , 2001, The Journal of allergy and clinical immunology.

[191]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[192]  E. Bremer Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy , 2013, ISRN oncology.

[193]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[194]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[195]  P. S. Andersen,et al.  Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.

[196]  P. Lakatos,et al.  Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? , 2010, Current drug targets.

[197]  D. Salinger,et al.  Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies , 2011, Clinical pharmacokinetics.

[198]  A. Ashkenazi Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. , 2015, The Journal of clinical investigation.

[199]  Tom Vink,et al.  Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 , 2016, Molecular Cancer Therapeutics.

[200]  T. Igawa,et al.  Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131 , 2013, Protein engineering, design & selection : PEDS.

[201]  K Dane Wittrup,et al.  Biophysical properties of the clinical-stage antibody landscape , 2017, Proceedings of the National Academy of Sciences.

[202]  T. Igawa,et al.  pH-dependent antigen-binding antibodies as a novel therapeutic modality. , 2014, Biochimica et biophysica acta.

[203]  T. Igawa,et al.  Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity , 2014, mAbs.

[204]  A. D. de Vos,et al.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.

[205]  J. Nezu,et al.  Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases , 2017, Scientific Reports.

[206]  G. Thurston,et al.  Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs , 2017, Molecular Cancer Therapeutics.

[207]  P. Hass,et al.  An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. , 1998, Blood.

[208]  K. Gregersen,et al.  Single-Batch Production of Recombinant Human Polyclonal Antibodies , 2010, Molecular biotechnology.

[209]  T. Hanke,et al.  Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists , 2003, The Journal of experimental medicine.

[210]  Lisa J. Bernstein,et al.  A strategy for risk mitigation of antibodies with fast clearance , 2012, mAbs.

[211]  N. Warne,et al.  Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[212]  Jesse A. Stevenson,et al.  Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics , 2014, mAbs.

[213]  M. Breyer,et al.  Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys , 2016, mAbs.

[214]  Rodrigo Dienstmann,et al.  Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. , 2015, Cancer discovery.

[215]  D. Corti,et al.  Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease , 2016, Current Opinion in Immunology.

[216]  M. Little,et al.  A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells , 2014, mAbs.

[217]  A. Bardelli,et al.  MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations , 2016, Science Translational Medicine.

[218]  C. Laurell,et al.  Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. , 1974, Clinical chemistry.

[219]  Wolfgang Schaefer,et al.  The use of CrossMAb technology for the generation of bi- and multispecific antibodies , 2016, mAbs.

[220]  F. Theil,et al.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins , 2016, Journal of immunology research.

[221]  J. Byrd,et al.  A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. , 2014, Blood.

[222]  R. Bateman,et al.  Stop Alzheimer’s before it starts , 2017, Nature.

[223]  Napoleone Ferrara,et al.  Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.

[224]  C. Volz,et al.  Antibody therapies and their challenges in the treatment of age-related macular degeneration. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[225]  Matthew J. Newman,et al.  A review of blinatumomab, a novel immunotherapy , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[226]  B. Burnett,et al.  Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans , 2015, Nutrition Journal.

[227]  M. Mcnamara,et al.  OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..

[228]  Herren Wu,et al.  Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)* , 2006, Journal of Biological Chemistry.

[229]  M. Shirts,et al.  Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange , 2011, Pharmaceutical Research.

[230]  Leonard A. Smith,et al.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[231]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[232]  W WarneNicholas,et al.  Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011 .

[233]  K. Garber Industry 'road tests' new wave of immune checkpoints , 2017, Nature Biotechnology.

[234]  T. Hanke,et al.  Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases , 2005, Annals of the rheumatic diseases.

[235]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[236]  K Dane Wittrup,et al.  Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. , 2013, Protein engineering, design & selection : PEDS.

[237]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[238]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[239]  Yang Wang,et al.  Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches , 2014, mAbs.

[240]  Kang-Yell Choi,et al.  Screening-based approaches to identify small molecules that inhibit protein–protein interactions , 2017, Expert opinion on drug discovery.

[241]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[242]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[243]  Richard O'Kennedy,et al.  Coming-of-Age of Antibodies in Cancer Therapeutics. , 2016, Trends in pharmacological sciences.

[244]  Melanie A. Huntley,et al.  Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies , 2016, Neuron.

[245]  H. Wajant,et al.  Principles of antibody-mediated TNF receptor activation , 2015, Cell Death and Differentiation.

[246]  J. Desjarlais,et al.  Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. , 2012, The Journal of allergy and clinical immunology.

[247]  Jihong Wang,et al.  Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.

[248]  G. A. Lazar,et al.  Modulation of antibody effector function. , 2011, Experimental cell research.

[249]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[250]  Paul H. Bessette,et al.  Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index , 2013, Science Translational Medicine.

[251]  S. Vermeire,et al.  AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. , 2016, Journal of Crohn's & colitis.

[252]  Herren Wu,et al.  Insights into the molecular basis of a bispecific antibody's target selectivity , 2015, mAbs.

[253]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.

[254]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[255]  D. Scheinberg,et al.  Opportunities and challenges for TCR mimic antibodies in cancer therapy , 2016, Expert opinion on biological therapy.

[256]  M. Robinson,et al.  Oligoclonal antibodies to target the ErbB family , 2015, Expert opinion on biological therapy.

[257]  K. Gunasekaran,et al.  Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies* , 2013, The Journal of Biological Chemistry.

[258]  R. Ober,et al.  Targeting FcRn for the modulation of antibody dynamics. , 2015, Molecular immunology.

[259]  D. Driver,et al.  FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys , 2012, Drug Metabolism and Disposition.

[260]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[261]  P. Parren,et al.  Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy? , 2016, Current opinion in immunology.

[262]  Y. Yonezawa,et al.  TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2 , 2015, Scientific Reports.

[263]  M. Tsuchiya,et al.  A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. , 2005, Blood.

[264]  M. Klempner,et al.  A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life , 2015, mAbs.

[265]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[266]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[267]  H. Yamamoto,et al.  Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies. , 1999, Hybridoma.

[268]  S. Iyer,et al.  Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[269]  Thomas Emrich,et al.  Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics , 2014, Proceedings of the National Academy of Sciences.

[270]  G. Proetzel,et al.  Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. , 2014, Methods.

[271]  P. Cooper,et al.  FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric‐coated capsules in cynomolgus macaques , 2016, Pharmacology research & perspectives.

[272]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[273]  J. Desjarlais,et al.  Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor , 2013, Arthritis & rheumatology.

[274]  B. Carr,et al.  Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences , 2011, Drug Metabolism and Disposition.

[275]  J. Foidart,et al.  Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma. , 2012, American journal of respiratory cell and molecular biology.

[276]  R. Tarran,et al.  Inhaled protein/peptide-based therapies for respiratory disease , 2016, Molecular and Cellular Pediatrics.

[277]  A. Urtti,et al.  Pharmacokinetic aspects of retinal drug delivery , 2017, Progress in Retinal and Eye Research.

[278]  Sunghoon Kim,et al.  A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells , 2014, mAbs.

[279]  S. Kadono,et al.  Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant , 2013, mAbs.

[280]  K. Scearce-Levie,et al.  Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates , 2014, Science Translational Medicine.

[281]  P. Hass,et al.  Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. , 2016, Molecular pharmaceutics.

[282]  C. Uyttenhove,et al.  PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[283]  B. Jakobsen,et al.  Molecular Immunology , 2015 .

[284]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[285]  N. Tsurushita,et al.  An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.

[286]  M. Little,et al.  A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells , 2015, mAbs.

[287]  Saileta Prabhu,et al.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.

[288]  V. Stoll,et al.  A potent erythropoietin-mimicking human antibody interacts through a novel binding site. , 2007, Blood.

[289]  Kiran Mukhyala,et al.  Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.

[290]  V. Oganesyan,et al.  pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling , 2014, The Journal of Biological Chemistry.

[291]  P. Humphries,et al.  The Blood-Retina Barrier , 2013 .

[292]  Rachel M. Devay,et al.  Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. , 2017, Bioconjugate chemistry.

[293]  S. Cooperband,et al.  Selective Destruction of Target Cells by Diphtheria Toxin Conjugated to Antibody Directed against Antigens on the Cells , 1970, Science.

[294]  Radha Ramakrishnan,et al.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development , 2017, The AAPS Journal.

[295]  Theo Rispens,et al.  Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.

[296]  M. Curran,et al.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..

[297]  L. Boulet,et al.  Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.

[298]  Susan Hua,et al.  Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[299]  M. van Lookeren Campagne,et al.  Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy , 2015, CPT: pharmacometrics & systems pharmacology.